Article
An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Jul 2022
Singh Jeshika, Bourke Siobhan, Dyer Matthew, Devlin Nancy, Longworth Louise
Abstract excerpt
OBJECTIVES: Treatment switching from control to treatment after disease progression is common in oncology trials. Analyses of survival data typically adjust for this bias, but such adjustments are rarely performed in analyses of patient-reported outcomes. This analysis aimed to examine the impact of adjusting for treatment switching on estimated treatment effects on 5-level version of EQ-5D (EQ-5D-5L) utilities...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.